Date: 2014-06-03
Type of information: Nomination
Compound: chief scientific officer, vice president
Company: Kymab (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 3, 2014, Kymab announced the appointment of Steve Arkinstall as chief scientific officer and Nigel Clark as vice president and head of business development.
Steve Arkinstall brings overs 25 years’ experience across biopharmaceutical research and development, having worked across several disease areas and specialising in drug target validation, R&D strategic design, antibody discovery and protein engineering. He joins Kymab from Merck Serono, where over his 16 year career he has held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of Global Technologies and External Innovation. Prior to joining Serono, he was in research at GlaxoWellcome. Steve is a respected leader in drug discovery and a global expert across a range of therapeutic, scientific and technical areas supporting drug discovery and development.
Nigel Clark has 20 years’ experience in the biopharmaceutical industry at both publicand private companies. He is a recognised deal maker and has completed over 20 major transactions. He was previously Chief Business Officer at Syntaxin and negotiated the sale of the company to Ipsen Pharma for €158 million. Prior to Syntaxin, Nigel was Head of Business Development at Vernalis, where he was responsible for commercial operations, a role he held for seven years.
Financial terms:
Latest news:
Is general: Yes
